Last reviewed · How we verify
Dexamethasone 0.1%
Dexamethasone 0.1% is a Small molecule drug developed by Tel-Aviv Sourasky Medical Center. It is currently FDA-approved. Also known as: Tobradex, Sterodex.
At a glance
| Generic name | Dexamethasone 0.1% |
|---|---|
| Also known as | Tobradex, Sterodex |
| Sponsor | Tel-Aviv Sourasky Medical Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Management of Pain in Lumbar Arthrodesis (PHASE4)
- A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) (PHASE3)
- Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A) (PHASE1, PHASE2)
- Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) (PHASE3)
- Perineural vs Intravenous Dexamethasone as an Adjuvant to Brachial Plexus Block in Pediatric Hand Surgery (NA)
- Comparison of the Effects of Moderate- and High-Dose Glucocorticoids on Postoperative Recovery (NA)
- An Open-Label, Single-Arm, Dose-Escalation Phase I Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of EDB-102 in Patients With EGFR L858R-Mutant, Third-Generation TKI-Resistant Advanced Non-Small Cell Lung Cancer With Liver Metastases (PHASE1)
- Postoperative Pain Monitoring With ANI in Lumbar Spine Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dexamethasone 0.1% CI brief — competitive landscape report
- Dexamethasone 0.1% updates RSS · CI watch RSS
- Tel-Aviv Sourasky Medical Center portfolio CI
Frequently asked questions about Dexamethasone 0.1%
What is Dexamethasone 0.1%?
Dexamethasone 0.1% is a Small molecule drug developed by Tel-Aviv Sourasky Medical Center.
Who makes Dexamethasone 0.1%?
Dexamethasone 0.1% is developed and marketed by Tel-Aviv Sourasky Medical Center (see full Tel-Aviv Sourasky Medical Center pipeline at /company/tel-aviv-sourasky-medical-center).
Is Dexamethasone 0.1% also known as anything else?
Dexamethasone 0.1% is also known as Tobradex, Sterodex.
What development phase is Dexamethasone 0.1% in?
Dexamethasone 0.1% is FDA-approved (marketed).
Related
- Manufacturer: Tel-Aviv Sourasky Medical Center — full pipeline
- Also known as: Tobradex, Sterodex
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing